PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver disease |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 45 |
| PubMedID- 26147768 | Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. |
| PubMedID- 23226654 | Introduction: non-alcoholic fatty liver disease (nafld) is associated with type 2 diabetes (t2dm) and the metabolic syndrome, and can progress to chronic liver disease. |
| PubMedID- 24667697 | The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
| PubMedID- 23578506 | Objective: to explore the liver disease spectrum in patients with type 2 diabetes (t2dm) and the risk factors of non-alcoholic fatty liver disease (nafld). |
| PubMedID- 22156706 | We examined the prevalence of advanced liver disease in people with type 2 diabetes and analysed the effectiveness of liver function tests (lfts) as a screening tool. |
| PubMedID- 22787177 | Despite higher susceptibility to nonalcoholic fatty liver disease in patients with type 2 diabetes, a similar alt and ast elevation was observed in a type 1 diabetes study of ly2605541 (17). |
| PubMedID- 20625647 | Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
| PubMedID- 22561686 | Fatty liver disease is associated with obesity and type 2 diabetes, and hepatic lipid accumulation may contribute to insulin resistance. |
| PubMedID- 21664213 | Due to the worldwide surge in obesity and type 2 diabetes, the increased incidence of nonalcoholic fatty liver disease (nafld) is a major concern for the public health. |
| PubMedID- 25854973 | The prevalence of cld differs between countries, affecting approximately 300 million people in china,1 29 million in the european union2 and more than 8 million cases in australia.3 the leading causes of cld are viral hepatitis b and c (hcv), harmful alcohol consumption and metabolic fatty liver disease associated with obesity and type 2 diabetes.1–7 regardless of aetiology, most of the morbidity and mortality from cld occurs among individuals with cirrhosis, who are at risk of developing complications including ascites, hepatic encephalopathy, variceal haemorrhage and liver cancer. |
| PubMedID- 25303488 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 26573193 | [relationship of socioeconomic status and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus]. |
| PubMedID- 23671610 | In addition, nonalcoholic fatty liver disease (nafld) is associated with insulin resistance, type 2 diabetes, metabolic syndrome, atherosclerosis [6]–[7], and a greater risk of cardiovascular events [8]. |
| PubMedID- 26573192 | Objective: to investigate the effect of body mass index (bmi) on new-onset non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 23469233 | This study provides the gene expression profile data of type 2 diabetic mouse liver by high-throughput sequencing, and demonstrates the main biological processes, pathways, fatty acid and glucose metabolism related key enzyme genes and liver diseases correlated with type 2 diabetes. |
| PubMedID- 24919218 | [advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus]. |
| PubMedID- 23954219 | Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 24071688 | Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin. |
| PubMedID- 23043895 | Fatty liver disease is epidemiologically associated with type 2 diabetes (t2d), leading to a speculation of a reciprocal cause-effect relationship and a vicious cycle of pathology. |
| PubMedID- 25739820 | We identified and summarized longitudinal studies that, supporting the association of nonalcoholic fatty liver disease with either type 2 diabetes mellitus or metabolic syndrome, suggest that nonalcoholic fatty liver disease precedes the development of both conditions. |
| PubMedID- 20353583 | This study aimed to examine the importance of serum endotoxin and inflammatory markers in non-alcoholic fatty liver disease (nafld) patients, with and without type 2 diabetes mellitus (t2dm), and to explore the effect of treatment with a lipase inhibitor, orlistat, on their inflammatory status. |
| PubMedID- 25966055 | Role of apn and tnf-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease. |
| PubMedID- 22956978 | Virtually the entire spectrum of liver disease is seen in patients with type 2 diabetes. |
| PubMedID- 25877002 | The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus. |
| PubMedID- 25885947 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 22209682 | Nonalcoholic fatty liver disease is frequently associated with type 2 diabetes; however, this idea is challenged by recent studies because hepatic steatosis is not always associated with insulin resistance (ir). |
| PubMedID- 23113121 | Nafld is a common liver disease strongly associated with obesity, type 2 diabetes mellitus and hyperlipidemia (2). |
| PubMedID- 26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. |
| PubMedID- 21478462 | Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study. |
| PubMedID- 26198953 | Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province. |
| PubMedID- 23332087 | This critical review of the published work aims to highlight the most recent basic and clinical data underlying the development of type 2 diabetes, in those with non-alcoholic fatty liver disease. |
| PubMedID- 23869321 | Quoted that “non-alcoholic fatty liver disease is associated with type 2 diabetes and the metabolic syndrome.”[1] however, in the present report,[1] the retrospective review is done. |
| PubMedID- 22024083 | Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. |
| PubMedID- 21596453 | Serum fgf21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hscrp levels independently. |
| PubMedID- 24751397 | Similar findings were observed by several other rodent studies [22,23] and have recently been confirmed in liver biopsies of patients with nafld, highlighting the clinical relevance of cd36 in human liver diseases associated with obesity and type 2 diabetes [24]. |
| PubMedID- 23489256 | Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld). |
| PubMedID- 26454513 | Clinically significant chronic liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study. |
| PubMedID- 22393561 | Fatty liver disease in type 2 diabetes: common and often unmanaged. |
| PubMedID- 24402015 | Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. |
| PubMedID- 22239625 | Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. |
| PubMedID- 21862168 | Aim: to clarify the association between serum sex hormone-binding globulin (shbg) levels and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes. |
| PubMedID- 26011302 | Background: nonalcoholic fatty liver disease (nafld) is associated with obesity, type 2 diabetes mellitus, and dyslipidemia. |
| PubMedID- 22927782 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. |
| PubMedID- 25278764 | Non-alcoholic fatty liver disease (nafld) leads to obesity and type 2 diabetes.10,11 hepatic tg content in nafld is directly related to the free fatty acid uptake by liver. |
| PubMedID- 21457442 | Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. |
Page: 1